DLL3 and central nervous system cancer: In addition to SCLC, Spino et al. measured DLL3 expression in 34 different types of cancers by bioinformatics methods, revealing that DLL3 expression in isocitrate dehydrogenase (IDH)-mutant glioma, particularly in 1p/19q co-deleted subsets, is higher than that of IDH-wild-type glioblastoma [19].